Background And Aims: The present prospective, randomised study was done to evaluate induction characteristics with bispectral (BIS) index guided infusion of propofol and etomidate.

Materials And Methods: After institutional ethical committee approval, 70 patients, aged 18-60 years, American Society of Anaesthesiologists (ASA) I and II scheduled for elective surgery were included. Patients were randomly allocated into one of the two groups. In Group E, patients received etomidate infusion at a rate of 0.07 mg kg min and in Group P, received propofol infusion of 0.7 mg kg min. Time from start of infusion to loss of palpebral reflex (T), loss of verbal command (T), BIS to reach 50 (T), mean induction dose and incremental dose of each drug required to keep BIS, haemodynamic parameters and adverse effects like pain, myoclonus, apnoea and postoperative nausea and vomiting (PONV) were also noted.

Results: TT, and T was faster in E as compared to group and was statistically significant for all parameters. Mean induction dose of drug required till BIS 50 was 2.68 ± 0.56 mg kg and 0.242 ± 0.11 mg kg in group and E, respectively. There was a significant difference between the groups with group E requiring incremental dose in a significant proportion of patients ( = 0.004). There was a significant decrease in MAP in group as compared to E. In group P, more number of patients experienced pain and had apnoea episode as compared to group E. ( < 0.001). Myoclonus was observed in group E only ( = 0.016).

Conclusion: BIS-guided titration of propofol and etomidate infusion for induction did not result in reduction of the dose, haemodynamic variations and other effects.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641050PMC
http://dx.doi.org/10.4103/ija.IJA_221_20DOI Listing

Publication Analysis

Top Keywords

etomidate infusion
12
compared group
12
group
9
propofol etomidate
8
groups group
8
induction dose
8
incremental dose
8
dose drug
8
drug required
8
infusion
6

Similar Publications

Background: Remimazolam is a novel ultra-short-acting benzodiazepine known for its hemodynamic stability over propofol. However, its hemodynamic effects compared to those of etomidate are not well established. This study aimed to determine whether the use of remimazolam is non-inferior to etomidate with regard to the occurrence of post-induction hypotension in patients undergoing coronary arterial bypass grafting.

View Article and Find Full Text PDF

Purpose: Severe Cushing's syndrome (SCS) is a life-threatening endocrine condition that requires prompt medical intervention. Intravenous etomidate infusion is considered to be the most effective in rapid cortisol overproduction inhibition. This single-center retrospective study aimed to present the safety and effectiveness of intravenous, low-dose, lipid-formulated etomidate infusion in patients with SCS.

View Article and Find Full Text PDF

Discovery of thioetomidate derivatives as rapid recovery hypnotics without adrenocortical suppression.

Bioorg Chem

January 2025

Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, School of Pharmacy, Jiangsu Ocean University, Lianyungang 222005, China. Electronic address:

Intravenous anesthetics play a crucial role during surgery. Etomidate, a commonly used intravenous anesthetic agent, is prized for its rapid onset and smooth induction of anesthesia. However, it has a pronounced adverse effect on adrenal function suppression.

View Article and Find Full Text PDF

Objectives: To compare the safety and efficacy of ketamine and etomidate as induction agents to facilitate emergent endotracheal intubation.

Data Sources: We searched MEDLINE, Embase, Cochrane Clinical Trials Register, and ClinicalTrials.gov from inception to April 3, 2024.

View Article and Find Full Text PDF
Article Synopsis
  • Etomidate is a short-acting anesthetic gaining attention due to its potential for abuse, especially when mixed in e-cigarettes, yet it has not been researched for its abuse potential until now.
  • This study used tests on male mice and rats to evaluate etomidate's rewarding and reinforcing effects, finding that specific doses caused conditioned place preference and led to the self-administration of the drug.
  • Results indicate that etomidate has significant abuse potential in rodents, demonstrating rewarding effects, which raises concerns about its possible abuse in humans.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!